IN MULTIPLE MYELOMA TREATMENT,There are MANY
factors to
consider.Efficacy and safety
always come
first, but delivery is
key to the
experience.
While patients often prefer oral administration, common regimens
include a combination of oral and non-oral treatments.1
Manual subcutaneous injection is fast, but can be physically demanding to administer.2-4
IV delivery is familiar—but in some cases requires longer chair time and monitoring.5,6
Subcutaneous syringe pump is hands-free, yet may introduce logistical complexity to set up.7-9
Treatment administration can weigh
heavy on everyone.
Consider how multiple myeloma treatment administration may be impacting your patients
Actor portrayal.
Have any of your patients with multiple myeloma reported
pain or discomfort from treatment administration?
Studies show that treatment administration can cause some pain or discomfort10-12
Patients receiving IV infusions may experience pain related to cannulation, while in subcutaneous administration, larger needle diameters have been linked to increased pain and bruising at the injection site.10-12
Multiple myeloma treatment
administration burdens can
extend from patients to providers.
Actor portrayal.
Have your nurses shared how
their experiences differ across
administration options?
The weight of treatment administration can add up and disrupt daily workflow, placing a strain on your practice.
What if you could build your ideal administration option?
Select the top 3 attributes that would be most impactful for your patients and practice:
Start a conversation with your team about how
to support the needs of your patients, staff, and practice.
Share this site with a teammate or colleague
IV=intravenous.
REFERENCES: 1. Ayto R, Annibali O, Biedermann P, et al. The EASEMENT study: a multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies. Eur J Haematol. 2024;112(6):889-899. doi:10.1111/ejh.14180 2. Green P, Schneider A, Lange J. Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products. MAbs. 2024;16(1):2402713. doi:10.1080/19420862.2024.2402713 3. Badkar AV, Gandhi RB, Davis SP, LaBarre MJ. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Des Devel Ther. 2021;15:159-170. doi:10.2147/DDDT.S287323 4. MacDonald V, Wilson K, Sonne MWL, Keir PJ. Grip type alters maximal pinch forces in syringe use. Hum Factors. 2017;59(7):1088-1095. doi:10.1177/0018720817720339 5. Mayo Clinic. Chemotherapy. Mayo Clinic. Published March 5, 2020. Accessed August 26, 2025. https://www.mayoclinic.org/tests-procedures/chemotherapy/about/pac-20385033 6. McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting. Pharmacoecon Open. 2023;7(1):3-36. doi:10.1007/s41669-022-00361-3 7. Franzese C, Hawthorne J, Katsaros D, Coyne M. Patient experience and improvement opportunities in self-administered, large-volume subcutaneous infusions at home. Patient Prefer Adherence. 2025;19:2459-2491. doi:10.2147/PPA.S515565 8. Marie Curie. Syringe drivers in palliative care. Marie Curie. Published August 5, 2024. Accessed August 26, 2025. https://www.mariecurie.org.uk/professionals/palliative-care-knowledge-zone/syringe-drivers 9. AKAS Infusions. How are infusion pumps and syringe pumps different? AKAS Infusions. Published January 20, 2025. Accessed August 26, 2025. https://www.akasinfusions.com/blog/how-are-infusion-pumps-and-syringe-pumps-different/ 10. Gill HS, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol. 2007;1(5):725-729. doi:10.1177/193229680700100517 11. Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996. doi:10.1007/s12325-019-01101-6 12. Wheeler C, Furniss D, Galal-Edeen GH, Blandford A, Franklin BD. Patients' perspectives on the quality and safety of intravenous infusions: a qualitative study. J Patient Exp. 2020;7(3):380-385. doi:10.1177/2374373519843921
©2025 Sanofi-aventis Groupe. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate.
MAT-GLB-2503935-v1.0-10/2025
MAT-US-2511325-v1.0-10/2025